The ViaLuxe™ Laser System
When it comes to a successful glaucoma intervention, SEEING IS BELIEVING. Only ViaLase® offers a truly noninvasive solution that combines femtosecond laser precision and the accuracy of micron-level image guidance in one revolutionary glaucoma treatment.
See our Technology in action
With a leadership team that has vast experience developing and commercializing the first femtosecond lasers for ophthalmic surgery; ViaLase is now bringing that expertise and innovation to glaucoma patients.
First In-Human Study Results at 24 Months
34.6%
mean IOP lowering at 24 months
No serious adverse events related to the treatment at any timepoint
Study Design:
The 24-month prospective, non-randomized, single-center, interventional, single-arm trial evaluated 17 eyes with open angle glaucoma following FLigHT treatment, which consisted of the creation of a single channel through the trabecular meshwork and into Schlemm's canal.
Reference:
Nagy Z.Z., Kranitz K., Ahmed I.I.K., De Francesco T., Mikula E. & Juhasz T., First-in-Human Safety Study of Femtosecond Laser Image-Guided Trabeculotomy for Glaucoma Treatment, Ophthalmology Science, Volume 3, Issue 4, 100313, December 2023 Page 1: Efficacy and Safety Data
Durability of FLigHT Treatment at 24 Months
Well defined channels clearly visible at 24 months by proprietary on-board ViaVue™ gonioscopic camera and anterior segment OCT, with no evidence of closure or scarring.
Disclaimer:
Channel is validated by third-party OCT
Reference:
Nagy Z.Z., Kranitz K., Ahmed I.I.K., De Francesco T., Mikula E. & Juhasz T., First-in-Human Safety Study of Femtosecond Laser Image-Guided Trabeculotomy for Glaucoma Treatment, Ophthalmology Science, Volume 3, Issue 4, 100313, December 2023 Page 1: Efficacy and Safety Data